Phase I randomized dose-ascending placebo-controlled trials of ferroquine - a candidate anti-malarial drug - in adults with asymptomatic Plasmodium falciparum infection
Authors:
- Ghyslain Mombo-NgomaGMGhyslain Mombo-Ngoma
- Christian SupanCSChristian Supan
- Matthias P Dal-BiancoMDMatthias P Dal-Bianco
- Michel A MissinouMMMichel A Missinou
- Pierre-Blaise MatsieguiPMPierre-Blaise Matsiegui
- Carmen L Ospina SalazarCSCarmen L Ospina Salazar
- Saadou IssifouSISaadou Issifou
- Daniel Ter-MinassianDTDaniel Ter-Minassian
- Michael RamharterMRMichael Ramharter
- Maryvonne KombilaMKMaryvonne Kombila
- Peter G KremsnerPeter G Kremsner
- Bertrand LellBLBertrand Lell
Open Access
- 1 March 2011
- journal article
- research article
- Published by Springer Nature in Malaria Journal
- Vol. 10 (1) , 53
Abstract
Background: The development and spread of drug resistantPlasmodium falciparumstrains is a major concern and novel anti-malarial drugs are, therefore, needed. Ferroquine is a ferrocenic derivative of chloroquine with proven anti-malarial activity against chloroquine-resistant and -sensitiveP. falciparumlaboratory strains.Methods: Adult young male aged 18 to 45 years, asymptomatic carriers ofP. falciparum, were included in two-dose escalation, double-blind, randomized, placebo-controlled Phase I trials, a single dose study and a multiple dose study aiming to evaluate oral doses of ferroquine from 400 to 1,600 mg.Results: Overall, 54/66 patients (40 and 26 treated in the single and multiple dose studies, respectively) experienced at least one adverse event, 15 were under placebo. Adverse events were mainly gastrointestinal symptoms such as abdominal pain (16), diarrhoea (5), nausea (13), and vomiting (9), but also headache (11), and dizziness (5). A few patients had slightly elevated liver parameters (10/66) including two patients under placebo. Moderate changes in QTc and morphological changes in T waves were observed in the course of the study. However, no adverse cardiac effects with clinical relevance were observed.Conclusions: These phase I trials showed that clinically, ferroquine was generally well-tolerated up to 1,600 mg as single dose and up to 800 mg as repeated dose in asymptomatic young male withP. falciparuminfection. Further clinical development of ferroquine, either alone or in combination with another anti-malarial, is highly warranted and currently underway.Keywords
This publication has 33 references indexed in Scilit:
- Evidence of Artemisinin-Resistant Malaria in Western CambodiaNew England Journal of Medicine, 2008
- Fixed‐Dose Pyronaridine‐Artesunate Combination for Treatment of Uncomplicated Falciparum Malaria in Pediatric Patients in GabonThe Journal of Infectious Diseases, 2008
- Geschichte und Zukunft der Medizinischen Forschung am Albert Schweitzer Spital in Lambaréné, GabunWiener klinische Wochenschrift, 2007
- Randomized Controlled Trial of Fosmidomycin-Clindamycin versus Sulfadoxine-Pyrimethamine in the Treatment of Plasmodium falciparum MalariaAntimicrobial Agents and Chemotherapy, 2007
- Randomized Dose-Ranging Controlled Trial of AQ-13, a Candidate Antimalarial, and Chloroquine in Healthy VolunteersPLoS Clinical Trials, 2007
- Artesunate-Clindamycin versus Quinine-Clindamycin in the Treatment ofPlasmodium falciparum Malaria: A Randomized Controlled TrialClinical Infectious Diseases, 2005
- Fosmidomycin‐Clindamycin forPlasmodium falciparumInfections in African ChildrenThe Journal of Infectious Diseases, 2004
- Long term effectiveness of antimalarial drugs in rheumatic diseasesAnnals of the Rheumatic Diseases, 1998
- Synthesis and Antimalarial Activity in Vitro and in Vivo of a New Ferrocene−Chloroquine AnalogueJournal of Medicinal Chemistry, 1997
- Treatment of Severe Chloroquine PoisoningNew England Journal of Medicine, 1988